Navigation Links
Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Date:12/10/2012

methasone in patients with relapsed or refractory MM.
  • Phase 1b investigator-sponsored trial in combination with Kyprolis in patients with relapsed or refractory MM who are refractory or intolerant to Velcade therapy. 
  • In the Phase 1 trial with ARRY-614, a dual p38/Tie2 inhibitor, the new formulation demonstrated improved bioavailability and inter-patient variability in our ongoing study of low or intermediate-1 risk Myelodysplastic Syndromes (MDS).  With this new formulation, peak plasma concentrations and overall exposures are higher than with the original formulation, possibly affording more extensive Tie2 inhibition. The ongoing Phase 1 dose escalation trial of the optimized ARRY-614 formulation may further our understanding of the contributions of these targets to the pathogenesis of MDS.  In our prior study in a similar population, we observed a 38% response rate for hematologic improvement in patients receiving the highest dose of the prior formulation. At this dose, ARRY-614 demonstrated multilineage hematologic improvement in 67% of the responders, improving two or more cytopenias (neutropenia, thrombocytopenia and/or anemia).  The most common drug related adverse events in this study included diarrhea and skin rash.

    After the presentations, the posters and presentation slides will be available to view and download in PDF format on Array's website at www.arraybiopharma.com.  ASH is the world's largest professional society concerned with the causes and treatments of blood disorders, and presentation of clinical trial results at the annual conference marks an important strategic milestone in the continued development of these two drugs.

    About Array BioPharma

    Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflict
    '/>"/>

    SOURCE Array Biopharma
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
    2. John A. Orwin Joins Array BioPharma Board Of Directors
    3. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
    4. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
    5. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
    6. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
    7. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
    8. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
    9. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
    10. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
    11. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
    (Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... state of the global Propanol market with a focus on the Chinese situation. Major ... Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua ...
    (Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
    (Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
    Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
    ... Md., Oct. 1 Novavax, Inc. (Nasdaq: NVAX ... the board,s corporate governance, compensation and finance committees, replacing board ... James Tananbaum who is retiring from the board. Mr. ... immunology products companies and joined the Novavax board in June ...
    ... Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) ... and affordable vaccines based on proprietary manufacturing technologies ... has initiated a Phase I human clinical trial ... Enrolment is ongoing and vaccination has commenced. The ...
    ... ... Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from ... ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits ...
    Cached Biology Technology:Novavax Announces Board of Director Changes 2Novavax Announces Board of Director Changes 3Medicago begins human clinical testing with its avian flu pandemic vaccine 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3
    (Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
    (Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
    (Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
    Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
    ... three-dimensional plasmon rulers, capable of measuring nanometer-scale spatial ... researchers with the U.S. Department of Energy (DOE),s ... with researchers at the University of Stuttgart, Germany. ... unprecedented details on such critical dynamic events in ...
    ... awarded the University of Colorado Boulder a six-year, ... long-term ecological changes in Colorado,s high mountains, both ... Awarded to CU-Boulder,s Institute of Arctic and Alpine ... students, including undergraduates, to continue key environmental studies ...
    ... upon previous efforts producing a high-quality de ... E. coli O104:H4 outbreak ... their collaborators at the University Medical Centre ... map of the genome and plasmids without ...
    Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4The complete map of the Germany E. coli O104 genome released 2
    ... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
    A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
    ... incubator-shaker, has the smallest footprint of all our ... x 680 mm (W x D) does not ... x 510mm). Available in 25 mm or 50 ... shaking applications requiring controlled speed and temperature ...
    Request Info...
    Biology Products: